Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439569 | 0.81 | TLR7 (0.37) | DRD4BCHEACHEBACE1 | |
| SCHEMBL5240088 | 0.81 | DRD4 (0.48) | SIGMAR1DRD4BCHEACHEBACE1 | |
| SCHEMBL6217467 | 0.75 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL11775261 | 0.74 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL636999 | 0.72 | CHRM2 (0.58) | SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL14439615 | 0.72 | LTA4H (0.54) | DRD4DRD2DRD3 | |
| SCHEMBL5595279 | 0.72 | LTA4H (0.54) | DRD4DRD2DRD3 | |
| SCHEMBL5595280 | 0.72 | LTA4H (0.54) | DRD4DRD2DRD3 | |
| SCHEMBL8805162 | 0.71 | DRD4 (0.46) | SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL2797370 | 0.71 | DRD4 (0.44) | DRD4BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | SIGMAR1 543/4885DRD4 3131/4885BCHE 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.